APP
GBT

Avantax Planning Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Avantax Planning Partners’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-143
Closed -$5K – 1300
2018
Q3 		$5K Buy
+143
New +$6.33K ﹤0.01% 1121

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avantax Planning Partners's GBT Position: Q4 2018 in Review

Avantax Planning Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2018, closing a stake of 143 shares — an estimated $5K sold.

Avantax Planning Partners first reported a position in GBT in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 190 funds tracked by Wall St. Rank hold GBT as of Q4 2018.

  • Avantax Planning Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 143 Global Blood Therapeutics, Inc. shares in Q4 2018, an estimated $5K.
  • Avantax Planning Partners first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Global Blood Therapeutics, Inc. position peaked at $5K in Q3 2018.
  • 190 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.